GSK announces succession plan for cfo

Simon Dingemans joins from Goldman Sachs

Simon Dingemans has been named as chief financial officer designate and executive director of GlaxoSmithKline (GSK) from 4 January 2011. He will succeed Julian Heslop, who is to retire as chief financial officer and executive director of the company at the end of March 2011.

Dingemans joins the pharmaceutical firm from Goldman Sachs where he is currently managing director and partner. He has more than 25 years’ experience in investment banking, including most recently as leader of Goldman Sachs' European M&A business and before that as head of UK Investment Banking. During this time he has built relationships and offered strategic advice across multiple industry sectors, including pharmaceuticals and consumer healthcare.

Dingemans has worked closely with GSK for many years, most recently helping to establish ViiV Healthcare, a specialist HIV company.

Andrew Witty, chief executive of GSK, said: ‘Simon's appointment as cfo reflects the need for GSK to operate with both creativity and continued financial discipline. He will also be responsible for delivering cost savings from our global restructuring programme and implementing further measures to simplify our operational model.’

You may also like

Manufacturing

Symbiosis expands sterile manufacturing capacity with fill/finish line qualification

Symbiosis has maintained a track record of successful GMP inspections with both the FDA and MHRA since it was founded
Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
Finance

New CGT centre in Bangkok to boost Southeast Asia’s biotech ecosystem

eXmoor Pharma and Siam Bioscience form a strategic partnership to establish leading cell and gene therapy services in Southeast Asia
Finance

Pfizer to acquire Metsera in $4.9bn deal, expanding obesity drug pipeline with next-generation incretin and amylin therapies

The deal strengthens Pfizer’s position in the fast-growing obesity market, with additional milestone payments of up to $2.3bn tied to key clinical and regulatory achievements
Finance

DaltonTx secures £4m in seed financing to build adaptive, AI-enabled discovery platforms

The UK-based technology company's adaptive platform will plug directly into pharma, biotech and CRO workflows, giving teams instant access to AI-enabled discovery
Manufacturing

Prange Pharma to acquire MSD Animal Health manufacturing site in Aprilia, Italy

Following completion, the site will relaunch as Aprilia Animal Health, focussing on contract manufacturing of animal health products whilst preserving jobs and expanding European expertise
Finance

EMV Capital subsidiary Moirai acquires Destiny Pharma’s XF-73 antibiotic platform

The XF drug platform, designed to prevent bacterial resistance and combat Gram-positive infections such as MRSA, represents a high-impact addition to EMV’s life sciences portfolio
Subscribe now